about the author

Endpoints Contributor

help@endpts.com

author articles

May the can­dle burn for­ev­er: Po­lite re­minders about the JP­Mor­gan con­fab

7 years ago
Biotech Voices

Ap­ta­hem – a Swedish biotech aim­ing to win the race against sep­sis

7 years ago

Fo­cus on tar­get­ed val­ue cre­ation and in­creased strate­gic man­age­ment is key to ad­dress chal­lenges with R&D ...

7 years ago

Io­n­is is fo­cused on treat­ing the un­treat­able with med­ical break­throughs for pa­tients

7 years ago

Cereno Sci­en­tif­ic is dri­ving a new par­a­digm of throm­bo­sis pre­ven­tion with­out as­so­ci­at­ed bleed­ing-risks

7 years ago

Nov­el he­pati­tis B virus nu­cle­o­cap­sid for­ma­tion in­hibitor CB-HBV-001 demon­strates ex­cel­lent an­ti-HBV ac­tiv­i­ty

7 years ago

How tri­al in­no­va­tion in Aus­tralia is get­ting ther­a­pies to pa­tients soon­er

7 years ago

With ac­cess to 1.4 bil­lion po­ten­tial Asia-Pa­cif­ic tri­al par­tic­i­pants, Novotech CRO can help get your drug to mar­ket ...

7 years ago

Guest col­umn: The re­al cost of drug de­vel­op­ment

7 years ago
R&D
Biotech Voices

A Swedish biotech is tar­get­ing throm­bo­sis us­ing the body's own de­fense sys­tem to pre­vent blood clots with low­er risk ...

7 years ago

The first FDA-ap­proved dig­i­tal pill — what it means for phar­ma

7 years ago

Guest col­umn: The 3 big waves re­shap­ing in­vest­ment strate­gies in ear­ly-stage biotech

7 years ago
Financing
Startups

Is the phar­ma busi­ness mod­el ready for pre­ci­sion med­i­cine?

7 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Sup­ply and De­mand Ex­pec­ta­tions and Im­bal­ances

7 years ago

Swedish Biotech Dex­Tech Med­ical shoots for bil­lion dol­lar prostate can­cer mar­ket — con­cludes phI­Ib study ear­ly

7 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Bull­ish Run to Con­tin­ue Amidst Signs of Greater Risk Aver­sion

7 years ago

Min­i­mal Resid­ual Dis­ease: A Prog­nos­tic Fac­tor Mov­ing the Nee­dle in Pa­tient Care

7 years ago

For­get about greed, Pres­i­dent Trump: the vil­lain re­spon­si­ble for high drug prices is in­ef­fi­cien­cy

7 years ago

Ele­phants can't jump? IDEA's Mike Rea says some Big Phar­ma play­ers are crush­ing old be­liefs

8 years ago
R&D
Special

The Evolv­ing Over­all Sur­vival Ex­pec­ta­tions of Pa­tients with Re­lapsed or Re­frac­to­ry Mul­ti­ple Myelo­ma

8 years ago

On this Rare Dis­ease Day, let's all com­mit to help­ing rec­og­nize the life and work of biotech gi­ant Hen­ri A. Ter­meer

8 years ago
Biotech Voices

The win­ners and losers of the Swedish biotech in­dus­try IPO fren­zy

8 years ago

How as­set sup­ply and de­mand is shap­ing bio­phar­ma­ceu­ti­cal deal­mak­ing

8 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2017: In­flu­ences and Hot Spots

8 years ago
First page Previous page 89101112 Next page Last page
A service from the Financial Times